Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited the company that manufactures ramucirumab (Cyramza(®), Eli Lilly and Company) to submit evidence of the clinical and cost effectiveness of the drug administered alone (monotherapy) or with paclitaxel (combination therapy) for treat...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Pharmacoeconomics
Päätekijät: Büyükkaramikli, Nasuh C., Blommestein, Hedwig M., Riemsma, Rob, Armstrong, Nigel, Clay, Fiona. J., Ross, Janine, Worthy, Gill, Severens, Johan, Kleijnen, Jos, Al, Maiwenn J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer International Publishing 2017
Aiheet:
Review Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5684255/
https://ncbi.nlm.nih.gov/pubmed/28656543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-017-0528-y
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia